C-TUQ USER MANUAL

Cancer Patient Tobacco Use Questionnaire

Developed by the NCI-AACR Cancer Patient Tobacco Use Assessment Task Force

Cancer Patient Tobacco Use Questionnaire (C-TUQ): Manual for Investigators

Contents

Introdu	uction	1
A.	What Is the C-TUQ?	1
B.	Rationale	1
C.	Background	2
Develo	opment and Validation of the C-TUQ	3
Survey	/ Items	3
A.	Structure	3
B.	Core Items	3
C.	Extension Items	4
D.	Specific Instructions	4
Questi	onnaire Administration	5
A.	Respondent Population	5
B.	Administration Methods	5
C.	Timing of Assessment	5
Access	sibility	5
Acknow	wledgments	7
NCI-A	ACR Cancer Patient Tobacco Use Assessment Task Force Membership	8
Contac	ct Information	9
Refere	ences	10
Cance	r Patient Tobacco Use Questionnaire (C-TUQ)	11
Cance	r Patient Tobacco Use Questionnaire (C-TUQ) - Spanish	20

Introduction

A. What Is the C-TUQ?

The Cancer Patient Tobacco Use Questionnaire (C-TUQ [pronounced "C.T.U.Q."]) is a 22-item self-report survey designed to capture information about tobacco use by cancer patients and cancer survivors. It is publicly available on the National Cancer Institute's (NCI) Grid-Enabled Measures website at www.gem-measures.org, and in the Appendix, for use. (No permission is required.) The questionnaire was developed by NCI and the American Association for Cancer Research (NCI-AACR) Cancer Patient Tobacco Use Assessment Task Force (Task Force). The C-TUQ survey tool is divided into five domains and includes a Core (short form of 4 items) and an Extension. The questionnaire is intended to be administered at key time points during periods of cancer treatment and recovery, as described below under "Questionnaire Administration."

B. Rationale

Findings from numerous research studies indicate that tobacco use, specifically smoking cigarettes, increases the risk of all-cause and cancer-specific mortality, and may also reduce therapeutic efficacy and increase the risks of cancer recurrence and treatment-related toxicity.[1-8] It is also known that smoking cessation improves the prognosis of patients diagnosed with cancer.[7] However, a substantial number of cancer patients and survivors continue to smoke after diagnosis.[9-13] More work is needed to fully understand how smoking cessation after diagnosis and during cancer treatment can affect treatment outcome or risks of cancer recurrence. In particular, comparisons need to be made between patients who stop smoking and then resume smoking during a period of therapy and patients who smoke continuously during therapy.[14] Furthermore, no standard measure had existed to identify and quantify tobacco use relative to the timeframes of cancer diagnosis, treatment, and survivorship.

General population measures of tobacco use history typically employ reference periods such as the past 7 or 30 days. Such items will generally not disambiguate tobacco use before or after diagnosis, surgery, and other events in cancer treatment and survivorship. For example, if a patient in his 3rd month of chemotherapy responds that he has not smoked cigarettes within the past 30 days, it may not be possible for researchers to discern whether he smoked during chemotherapy. The question "How long has it been since you last smoked a cigarette?" is captured in the proposed new questionnaire as a specific number of days, weeks, or years, which will permit researchers to compare that information with dates of events in the patient's cancer history. However, in some cases that item alone will not reveal important distinctions. If that patient in his 3rd month of chemotherapy responds that he smoked a cigarette today, he might have smoked regularly during therapy or abstained until today. In this case, item 7, which measures smoking frequency during time periods related to cancer diagnosis and treatment, provides the needed information.

Similarly, the use of other products (combustible, smokeless, and aerosol products [e.g., electronic cigarettes]) or of cessation assistance during timeframes relative to cancer diagnosis is captured in the newly developed instrument. As such, the C-TUQ collects the specific information needed to address understudied research questions regarding the effect of tobacco use on cancer treatment and other outcomes. On the other hand, conventional 7-day or 30-day abstinence reference periods (as in constructs 10a [smoking at all within past 30 days] or 10b [number of days smoked within past 30 days]) may be needed for reporting tobacco cessation in clinical trials and identifying current smokers or tobacco users for referral to tobacco use treatment.

(Excerpt from Land and colleagues [15])

C. Background

In 2013, NCI and AACR created a task force to develop recommendations for patient-reported tobacco use measures, the timing of assessments, and research priorities surrounding the need for tobacco use assessment in cancer patients and survivors. Based on the foundation that tobacco use is an important predictive, prognostic, and possibly confounding variable in cancer research, the Task Force recognized the need to address scientific questions, such as: (1) How does tobacco diminish treatment efficacy?, (2) What are the mechanisms of tobacco effects?, and (3) What is the improvement in prognosis with cessation after diagnosis? The Task Force also identified limitations in data collection, including a lack of tobacco use assessment in clinical trials or cancer treatment practice, inconsistency in tobacco use assessment methods, and little follow-up during or after cancer treatment. The C-TUQ was designed by the Task Force to address these questions and limitations, with the recommendation that it be broadly included in cancer research.[16]

Development and Validation of the C-TUQ

Initial versions of candidate items for the C-TUQ instrument were procured from a number of established tobacco surveillance instruments and were based on Task Force prioritization of constructs. Items were then adapted by the Task Force to capture information necessary in the setting of cancer research, such as cigarette smoking during time intervals surrounding cancer diagnosis and treatment. Expert survey methodologists from Westat, Inc. then modified items based on item design best practices and constructed the organization and flow of the questionnaire (e.g., skip patterns).

In the final stage of questionnaire development, all items for the C-TUQ were subjected to cognitive testing. Cognitive testing is a clinical interviewing method used to assess item comprehension, memory retrieval, response difficulty, and the accuracy of responses to evaluate the content validity, and overall adequacy, of self-report instruments.[17, 18] Cognitive testing of the C-TUQ was conducted on 30 cancer patients and survivors at the National Institutes of Health Clinical Center in Bethesda, MD (ClinicalTrials.gov Identifier: NCT02233842) to assess and improve C-TUQ measurement items.[15] During cognitive testing, items were evaluated based on intensive probing of respondents' answers, and the basis for those answers to identify problematic wording and ordering as well as erroneous assumptions inherent within the instrument. C-TUQ items were revised accordingly to ensure ease and the accuracy of responses and to establish content validity of the measure. For more details regarding C-TUQ development and validation, see Land and colleagues (2016).[16]

Survey Items

A. Structure

The C-TUQ comprises the C-TUQ Core (a short form of 4 items) and the C-TUQ Extension (18 items for additional assessment when feasible). The full set of 22 items is divided into 5 domains: (1) Basic Tobacco Use Information; (2) Cigarette Smoking in Relation to Cancer Diagnosis and Treatment; (3) Smoking Cessation, Cessation Products, and Assistance Methods; (4) Use of Other Products; and (5) Secondhand Smoke Exposure.

B. Core Items

Items 1, 4, 5, and 6 are the Core items of this questionnaire, measuring cigarette smoking history and current status. The Task Force recommends that all of these items be asked at baseline assessment

in all cancer research studies. Items 1 and 6 are the Core items recommended for follow-up assessment in all cancer research studies. Item 1 is not necessary to collect at follow-up if the patient responded "yes" at an earlier time point.

C. Extension Items

Items 2, 3, and 7–22 are considered Extension items to capture a more detailed history, the use of other tobacco products, cessation, and secondhand exposure. The Extension also includes smoking behavior during time periods specific to the cancer treatment trajectory, providing important data not available from general population questionnaires. The Task Force recommends that these items be included in baseline and follow-up assessments. In studies for which it is not feasible to include all Extension items, any subset of items may be selected.

D. Specific Instructions

- a. A participant may be deemed a current cigarette smoker using information collected in item 6 ["How long has it been since you last smoked a cigarette (even one or two puffs)?"]. Two common definitions of "current" smoking are (1) smoking within 30 days and (2) smoking within 1 year. Either of these can be determined from the responses to item 6.
- b. Items 10a and 10b may be considered alternatives to each other.
- c. The generic terms "treatment" and "cancer surgery" in item 7 can be replaced with specific terms to suit the research, or more specific terms may be included in parentheses. "Treatment" may be replaced with a therapy specific to the research study, such as "chemotherapy," "radiotherapy," or the name of an experimental agent. These terms can be helpful because cognitive testing revealed that patients have differing interpretations of the term "treatment." "Cancer surgery" may be replaced with a specific surgery, such as "mastectomy," as appropriate to the research context. Note that cognitive testing revealed that "surgery" may be interpreted as including biopsy or not.
- d. Cognitive testing revealed that patients who have experienced more than one primary cancer may be unsure which experience to consider when responding. If the goal of the research is to capture data relative to a particular cancer experience (e.g., the initial or most recent, instructions can be added to provide that clarification). At the end of Section 1, participants are given this instruction: "On the following page you will be asked about when you were first told you had cancer. If you have been diagnosed with cancer more than once, please answer these questions about your most recent cancer diagnosis." The phrase "most recent cancer diagnosis" in this instruction can be replaced with another term to suit the research context. For example, substitutions might be "your most recent diagnosis with breast cancer" or "your first cancer diagnosis."

- e. Additional note: Users should insert an appropriate patient study identifier and a date of completion and/or assessment time point fields.
- f. Tested versions of the questionnaire included skip instructions so that, for example, never smokers were instructed to skip over smoking history items. Questionnaire designers should incorporate skip instructions appropriate for the set of items and the respondent population.

Questionnaire Administration

A. Respondent Population

The C-TUQ instrument was designed for adult patients who have been diagnosed with any type of cancer, for patients who are currently receiving treatment for any type of cancer, for patients who have completed cancer treatment, and for cancer survivors.

B. Administration Methods

The C-TUQ was created to be paper-based and self-administered by an individual respondent in a confidential environment. It may also be completed electronically, with computer-aided administration. In addition, the instrument can be administered orally by an interviewer as needed, such as for respondents who have been diagnosed with visual or motor impairments or with reading or neurocognitive disabilities that may prevent them from self-administering the instrument.

C. Timing of Assessment

Longitudinal tobacco use assessment is important because although many patients quit tobacco use when they are diagnosed with cancer, many who quit will later resume use. Many important research questions require that tobacco use after diagnosis and throughout treatment be recorded.[14, 16] The Task Force recommends that the C-TUQ be administered, at a minimum, at the point of study entry and at the end of treatment. Other key time points during cancer treatment at which the C-TUQ may be administered include Day 1 of each chemotherapy cycle, at the onset and conclusion of radiation therapy, at the onset and conclusion of any other systemic cancer therapy, and 6–12 months after the end of cancer treatment. Monthly questionnaire administration is also an appropriate option.

Accessibility

The C-TUQ instrument is also available in Spanish (in this document). Future work will provide complete translations of the entire C-TUQ into other languages.

As mentioned in the "Questionnaire Administration" section, oral administration of the C-TUQ may be provided for respondents who are unable to self-administer the questionnaire due to physical or cognitive disabilities. Considerations are being made to create and implement a computerized version of the questionnaire.

Acknowledgments

We are deeply grateful for the generosity of the patients at the National Institutes of Health Clinical Center who shared their time and perspectives for the development of this questionnaire. The cognitive interview study and questionnaire completion was made possible by Jennifer Crafts, PhD (Westat, Inc.); Jasmine Folz (Westat, Inc.); James Gulley, MD, PhD (NCI); Eva Szabo, MD (NCI); David Schrump, MD, MBA (NCI); Veronica Chollette, MS, RN (NCI); Colleen Bond, ACNP (NCI); Arlene Berman, RN (NCI); Lisa Bengtson, RN (NCI); Yvonne Mallory, RN (NCI); Susan Perry, RN (NCI); Amy Hankin PA-C, (NCI); Deborah Allen, RN, OCN (NCI); and Arun Rajan, MD (NCI).

We thank Babita Das, PhD, Elizabeth Seaman, PhD (Cand), MHS, Gordon Willis, PhD, Rick Moser, PhD, Carolyn Reyes-Guzman, and Matthias Cohen Cosentino (NCI); and Dana Chomenko, MA, PMP, Kathryn Cleffi, MPH, RD, and Marcia McCann, MSW (BLH Technologies, Inc.) for their contributions to this manual development and editing. And we thank the members of the NCI-AACR Cancer Patient Tobacco Use Assessment Task Force for the development and dissemination of the C-TUQ.

NCI-AACR Cancer Patient Tobacco Use Assessment Task Force Membership

Name	Affiliation*
Jeffrey S. Abrams, MD	National Cancer Institute
Thomas H. Brandon, PhD	H. Lee Moffitt Cancer Center & Research Institute
Jan C. Buckner, MD	Mayo Clinic, North Central Cancer Treatment Group
Paul M. Cinciripini, PhD	University of Texas M.D. Anderson Cancer Center
K. Michael Cummings, PhD, MPH	Medical University of South Carolina
Carolyn Dresler, MD, MPA	Private Citizen
Sonia A. Duffy, PhD, RN, FAAN	Ohio State University
Michael C. Fiore, MD, MPH, MBA	University of Wisconsin Center for Tobacco Research and Intervention
Ellen R. Gritz, PhD	University of Texas M.D. Anderson Cancer Center
Dorothy Hatsukami, PhD	University of Minnesota
Roy S. Herbst, MD, PhD	Yale School of Medicine
Fadlo R. Khuri, MD, FACP	Emory School of Medicine
Stephanie R. Land, PhD	National Cancer Institute
Scott J. Leischow, PhD	Mayo Clinic
Sandra Mitchell, PhD, CRNP, AOCN	National Cancer Institute
Carol M. Moinpour, PhD	Fred Hutchinson Cancer Research Center
Jamie S. Ostroff, PhD	Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College
Sheila Prindiville, MD, MPH	National Cancer Institute
Nancy Rigotti, MD	Harvard Medical School, Massachusetts General Hospital
Linda Sarna, PhD, RN, FAAN, AOCN	University of California, Los Angeles
Robert A. Schnoll, PhD	University of Pennsylvania
Shimere Williams Sherwood, PhD	American Association for Cancer Research
Peter Shields, MD	Ohio State University
Benjamin Toll, PhD	Medical University of South Carolina
Kasisomayajula Viswanath, PhD	Harvard School of Public Health
Graham Warren, MD, PhD	Medical University of South Carolina, Alliance Prevention Committee

^{*}Professional affiliations as of December 2015.

Contact Information

To comment on the questionnaire and to share your experience with other users, please go to the NCI Grid-Enabled Measures website (www.gem-measures.org).

For additional information about the C-TUQ, please contact:

Stephanie R. Land, PhD National Cancer Institute (240) 276-6946 landsr@mail.nih.gov

References

- 1. Boorjian S, Cowan JE, Konety BR, et al. Bladder cancer incidence and risk factors in men with prostate cancer: results from Cancer of the Prostate Strategic Urologic Research Endeavor. J Urol 2007;177(3):883-7; discussion 887-8.
- 2. Kaufman EL, Jacobson JS, Hershman DL, et al. Effect of breast cancer radiotherapy and cigarette smoking on risk of second primary lung cancer. J Clin Oncol 2008;26(3):392-8.
- 3. National Cancer Institute. Smoking in cancer care (PDQ®) for health professionals: Poorer treatment response in cancer patients. http://www.cancer.gov/about-cancer/causes-prevention/risk/tobacco/smoking-cessation-hp-pdq#section/ 5 (2014 Jun 20; date last accessed).
- 4. National Cancer Institute. Smoking in cancer care (PDQ®) for health professionals: Smoking as a risk factor for second malignancy. http://www.cancer.gov/about-cancer/causes-prevention/risk/tobacco/smoking-cessation-hp-pdq#section/9 (2014 Jun 20; date last accessed).
- 5. Tucker MA, Murray N, Shaw EG, et al. Second primary cancers related to smoking and treatment of small-cell lung cancer. Lung Cancer Working Cadre. J Natl Cancer Inst 1997;89(23):1782-8.
- 6. Vaporciyan AA, Merriman KW, Ece F, et al. Incidence of major pulmonary morbidity after pneumonectomy: association with timing of smoking cessation. Ann Thorac Surg 2002;73(2):420-5; discussion 425-6.
- 7. US Department of Health and Human Services. The Health Consequences of Smoking -- 50 Years of Progress: A Report of the Surgeon General. In: United States Department of Health and Human Services. Public Health Service. Office of the Surgeon General; 2014.
- 8. Warren GW, Kasza KA, Reid ME, et al. Smoking at diagnosis and survival in cancer patients. Int J Cancer 2013;132(2):401-10.
- 9. Burris JL, Studts JL, DeRosa AP, et al. Systematic review of tobacco use after lung or head/neck cancer diagnosis: Results and recommendations for future research. Cancer Epidemiol Biomarkers Prev 2015; 10.1158/1055-9965.EPI-15-0257:Epub ahead of print.
- 10. Cataldo JK, Dubey S, Prochaska JJ. Smoking cessation: an integral part of lung cancer treatment. Oncology 2010;78(5-6):289-301.
- 11. Duffy SA, Khan MJ, Ronis DL, *et al.* Health behaviors of head and neck cancer patients the first year after diagnosis. Head Neck 2008;30(1):93-102.
- 12. Sardari Nia P, Weyler J, Colpaert C, et al. Prognostic value of smoking status in operated non-small cell lung cancer. Lung Cancer 2005;47(3):351-9.
- 13. Westmaas JL, Newton CC, Stevens VL, et al. Does a recent cancer diagnosis predict smoking cessation? An analysis from a large prospective US cohort. J Clin Oncol 2015;33(15):1647-52.
- 14. Land SR. Methodologic barriers to addressing critical questions about tobacco and cancer prognosis. J Clin Oncol 2012;30(17):2030-2.
- 15. Land SR, Warren GW, Crafts JL, et al. Cognitive testing of tobacco use items for administration to patients with cancer and cancer survivors in clinical research. Cancer 2016;122(11):1728-34.
- 16. Land SR, Toll BA, Moinpour CM, et al. Research priorities, measures, and recommendations for assessment of tobacco use in clinical cancer research. Clin Cancer Res 2016;22(8):1907-13.
- 17. Willis G. *Analysis of the Cognitive Interview in Questionnaire Design*. Oxford: UK: Oxford University Press; 2015.
- 18. Willis G. *Cognitive Interviewing*. Thousand Oaks, CA: Sage Publications; 2005.

Cancer Patient Tobacco Use Questionnaire (C-TUQ)

Please access background information and instructions in the C-TUQ Manual and share your experience by visiting the Tobacco Use by Cancer Patients workspace at www.gem-measures.org, or by contacting Stephanie R. Land, National Cancer Institute, at 240-276-6946, or landsr@mail.nih.gov. Please also visit http://cancercontrol.cancer.gov/brp/tcrb/research_topic-tobacco-use.html for the latest information about NCI's initiatives related to tobacco use in the context of cancer screening, treatment, and survivorship.

Please use the following reference for this measure:

NCI-AACR Cancer Patient Tobacco Use Assessment Task Force. (2016) Cancer Patient Tobacco Use Questionnaire (C-TUQ). Retrieved from: https://cancercontrol.cancer.gov/brp/research/.

This questionnaire was developed by the NCI-AACR Cancer Patient Tobacco Use Assessment Task Force and tested in a cognitive interview study (ClinicalTrials.gov Identifier: NCT02233842).

- Items 1, 4, 5, and 6 are Core items, recommended for baseline assessment in all cancer research studies. Items 1 and 6 are the Core items recommended for follow-up assessments in all cancer research studies.
- The remaining items are considered Extension items, and are available for inclusion as needed in baseline and follow-up assessments.

See also:

Land, Warren, Crafts, Hatsukami, Ostroff, Willis, Chollette, Mitchell, Folz, Gulley, Szabo, Brandon, Duffy, Toll. Cognitive testing of tobacco use items for administration to cancer patients and survivors in clinical research, *Cancer*. 2016;122(11):1728-1734. doi:10.1002/cncr.29964.

Land, Toll, Moinpour, Mitchell, Ostroff, Hatsukami, Duffy, Gritz, Rigotti, Brandon, Prindiville, Sarna, Schnoll, Herbst, Cinciripini, Leischow, Dresler, Fiore, Warren. Research priorities, measures, and recommendations for assessment of tobacco use in clinical cancer research, *Clinical Cancer Research*. 2016;22(8):1907-1913. doi:10.1158/1078-0432.CCR-16-0104.

CANCER PATIENT TOBACCO USE QUESTIONNAIRE (C-TUQ)

Section 1. Basic Tobacco Use Information

1.	Have you smoked at least 100 cigarettes (5 packs=100 cigarettes) in your entire life?			
	☐ Yes ☐ No ☐ Don't know/Not sure			
2.	How old were you when you first smoked a cigarette (even one or two puffs)?			
	Years old			
3.	How old were you when you first began smoking cigarettes regularly?			
	Years old			
	☐ Check here if you have never smoked cigarettes regularly.			
4.	How many total years have you smoked (or did you smoke) cigarettes? Do not count any time you may have stayed off cigarettes.			
	Years If you smoked less than one year, write "1."			
5.	On average when you have smoked, about how many cigarettes do you (or did you) smoke a day?			
	A pack usually has 20 cigarettes in it.			
	Number of cigarettes per day			

How long has it been since you last smoked a cigarette (even one or two puffs)? First check which one of the following choices applies to you. Then, if applicable, write a number on the line for how many days, weeks, months, or years it has been since your last cigarette.

	I smoked a cigarette today (at least one puff).
	1-7 days. Number of days since last cigarette:
	Less than 1 month. → Number of weeks since last cigarette:
	Less than 1 year. → Number of months since last cigarette:
	More than 1 year. → Number of years since last cigarette:
П	Don't know/Don't remember

INSTRUCTIONS

6.

On the following page you will be asked about when you were first told you had cancer. If you have been diagnosed with cancer more than once, please answer these questions about your most recent cancer diagnosis.

Please continue to the next page.

Section 2. Cigarette Smoking in Relation to Cancer Diagnosis and Treatment

7. During each of the following time frames, please indicate whether you smoked cigarettes every day, some days, or not at all.

	Smoked every day	Smoked some days	Didn't smoke at all	Don't know/ Not sure	Not applicable
a. The year before you were first told you had cancer					□ (I have not been diagnosed.)
b. After diagnosis, and before treatment started					□ (I have not been diagnosed.)
c. From 2 days before your last cancer surgery to 2 days after					□ (I have not had cancer surgery.)
d. During the course of treatment					□ (I have not received treatment.)
e. After treatment ended					(I have not completed treatment.)
f. Since your last visit to this clinic					(This is my first visit to this clinic.)

8.	Since you were first told you had cancer, which of the following products have you used <u>regularly</u> ?			
	Check all that apply.			
	 □ Cigarettes □ E-cigarettes or other electronic nicotine delivery system □ Traditional cigars, cigarillos or filtered cigars □ Pipes □ Hookah □ Clove cigarettes or kreteks □ Bidis □ Smokeless tobacco, like dip, chew, or snuff □ Snus □ Paan with tobacco, gutka, zarda, khaini □ None □ Other, <i>Please specify</i>: 			
9.	Since you were first told you had cancer, what was the longest time you stayed (or have stayed) off cigarettes?			
	☐ Stayed off cigarettes entire time since diagnosis			
	OR			
	 □ Stayed off cigarettes less than one day □ 1-7 days. → Number of days stayed off cigarettes: □ Less than 1 month. → Number of weeks stayed off cigarettes: □ Less than 1 year. → Number of months stayed off cigarettes: □ More than 1 year. → Number of years stayed off cigarettes: □ Don't know/Don't remember 			
Sect	ion 3. Smoking Cessation, Cessation Products, and Assistance Methods			
10a.	In the past 30 days, have you smoked any cigarettes, even one or two puffs?			
	☐ Yes ☐ No → Go to Question 11.			

10b.	In the past 30 days, on how many days did you smoke cigarettes?
	Number of days If none, write "0."
11.	Since you were first told you had cancer, which of the following products have you used to quit (or to stay off) smoking cigarettes?
	Check all that apply.
	 □ Nicotine patch □ Nicotine gum □ Nicotine lozenge □ Nicotine inhaler □ Nicotine nasal spray □ Bupropion (Wellbutrin, Zyban) □ Varenicline (Chantix) □ E-cigarettes or other electronic nicotine delivery system □ None □ Other, Please specify:
12.	Since you were first told you had cancer, what assistance have you used to quit (or to stay off) smoking cigarettes?
	Check all that apply.
	 □ Individual or group counseling □ A telephone helpline or quitline □ Books, pamphlets □ Videos □ A quit tobacco clinic, class, or support group □ An internet or web-based program □ A text message-based smoking cessation program □ Support of friends and family □ None □ Other, <i>Please specify</i>:
13.	Have your cancer doctors advised you to quit smoking cigarettes?
	 □ Yes □ No □ Not applicable; I have not smoked cigarettes since my diagnosis.

14.	In the past 30 days, have you been trying to quit (or trying to stay off) smoking cigarettes?
	□ Yes □ No → Go to Section 4.
15.	In the past 30 days, what, if any, products have you used to quit (or to stay off) smoking cigarettes?
	Check all that apply.
	 □ Nicotine patch □ Nicotine gum □ Nicotine lozenge □ Nicotine inhaler □ Nicotine nasal spray □ Bupropion (Wellbutrin, Zyban) □ Varenicline (Chantix) □ E-cigarettes or other electronic nicotine delivery system □ None □ Other, Please specify:
16.	In the past 30 days, what assistance have you used to quit (or to stay off) smoking cigarettes?
	Check all that apply.
	 □ Individual or group counseling □ A telephone helpline or quitline □ Books □ Pamphlets □ Videos □ A quit tobacco clinic, class, or support group □ An internet or web-based program □ A text message-based smoking cessation program □ Support of friends and family □ None □ Other, Please specify:

Please continue to the next page.

Section 4. Use of Other Products

17.	Which of the following products have you <u>ever</u> used regularly?
	Check all that apply.
	 □ Cigarettes □ E-cigarettes or other electronic nicotine delivery system □ Traditional cigars, cigarillos, or filtered cigars □ Pipes □ Hookah □ Clove cigarettes or kreteks □ Bidis □ Smokeless tobacco, like dip, chew, or snuff □ Snus □ Paan with tobacco, gutka, zarda, or khaini □ None □ Other, <i>Please specify</i>:
18.	In the past 30 days, which of the following products have you used?
	Check all that apply.
0 - 4	 □ Cigarettes □ E-cigarettes or other electronic nicotine delivery system □ Traditional cigars, cigarillos, or filtered cigars □ Pipes □ Hookah □ Clove cigarettes or kreteks □ Bidis □ Smokeless tobacco, like dip, chew, or snuff □ Snus □ Paan with tobacco, gutka, zarda, or khaini □ None □ Other, Please specify:
Secti	on 5. Second-Hand Smoke Exposure
19.	Are you currently living with a smoker?
	□ Yes
	□ No

20. In the past 30 days, have you...

	Yes	No
a. <u>Lived</u> in a place where other people smoked cigarettes indoors?		
b. Worked in a place where other people smoked cigarettes indoors?		

21.	Thinking of all your childhood and adult years, have you ever lived in a place where
	other people smoked cigarettes indoors?

Yes → In total, for about how many years?	 If less than 1,	write	"1."
No			

22. Thinking of all the years you have worked, have you <u>ever worked</u> in a place where other people smoked cigarettes indoors?

Yes →	In total, for about how many years?	If less than 1,	write	"1."
No				

Thank you for completing this questionnaire.

Cancer Patient Tobacco Use Questionnaire (C-TUQ) - Spanish

Please access background information and instructions in the C-TUQ Manual and share your experience by visiting the Tobacco Use by Cancer Patients workspace at www.gem-measures.org, or by contacting Stephanie R. Land, National Cancer Institute, at 240-276-6946, or landsr@mail.nih.gov. Please also visit http://cancercontrol.cancer.gov/brp/tcrb/research_topic-tobacco-use.html for the latest information about NCI's initiatives related to tobacco use in the context of cancer screening, treatment, and survivorship.

This Spanish language version was created by the National Institutes of Health Library and validated by native Spanish speaking NCI scientific personnel.

Please use the following reference for this measure:

NCI-AACR Cancer Patient Tobacco Use Assessment Task Force. (2016) Cancer Patient Tobacco Use Questionnaire (C-TUQ). Retrieved from: https://cancercontrol.cancer.gov/brp/research/.

This questionnaire was developed by the NCI-AACR Cancer Patient Tobacco Use Assessment Task Force and tested in a cognitive interview study (ClinicalTrials.gov Identifier: NCT02233842).

- Items 1, 4, 5, and 6 are Core items, recommended for baseline assessment in all cancer research studies. Items 1 and 6 are the Core items recommended for follow-up assessments in all cancer research studies.
- The remaining items are considered Extension items, and are available for inclusion as needed in baseline and follow-up assessments.

See also:

Land, Warren, Crafts, Hatsukami, Ostroff, Willis, Chollette, Mitchell, Folz, Gulley, Szabo, Brandon, Duffy, Toll. Cognitive testing of tobacco use items for administration to cancer patients and survivors in clinical research, *Cancer*. 2016;122(11):1728-1734. doi:10.1002/cncr.29964.

Land, Toll, Moinpour, Mitchell, Ostroff, Hatsukami, Duffy, Gritz, Rigotti, Brandon, Prindiville, Sarna, Schnoll, Herbst, Cinciripini, Leischow, Dresler, Fiore, Warren. Research priorities, measures, and recommendations for assessment of tobacco use in clinical cancer research, *Clinical Cancer Research*. 2016;22(8):1907-1913. doi:10.1158/1078-0432.CCR-16-0104.

CUESTIONARIO SOBRE EL CONSUMO DE TABACO DE PACIENTES CON CÁNCER CANCER PATIENT TOBACCO USE QUESTIONNAIRE (C-TUQ) (Spanish)

Sección 1. Información básica sobre el consumo de tabaco

1.	¿Ha fumado al menos 100 cigarrillos (5 cajetillas = 100 cigarrillos) en toda su vida?
	□ Sí □ No □ No sé / No estoy seguro
2.	¿A qué edad fumó su primer cigarrillo (incluso uno o dos pitadas)?
	años de edad
3.	¿A qué edad empezó a fumar cigarrillos <u>regularmente</u> ?
	años de edad
	☐ Marque aquí si nunca ha fumado cigarrillos regularmente.
4.	¿Durante cuántos años en total ha fumado o fumó cigarrillos? No incluya ningún período en el que haya dejado de fumar.
	Años Si fumó por menos de un año, escriba "1".
5.	En promedio, cuando fuma o ha fumado, ¿aproximadamente cuántos cigarrillos consume o consumió en un día?
	Una cajetilla suele tener 20 cigarrillos.
	Número de cigarrillos por día

6. ¿Cuándo fue la última vez que fumó cigarrillos (incluso uno o dos pitadas)?

Primero, marque la opción que corresponda. Luego, si es el caso, escriba el número sobre la línea para indicar cuántos días, semanas, meses o años han pasado desde que fumó el último cigarrillo.

□ Fumé un cigarrillo hoy (al menos una pitada).
□ De 1 a 7 días. → Número de días desde el último cigarrillo: _____
□ Menos de 1 mes. → Número de semanas desde el último cigarrillo: _____
□ Menos de 1 año. → Número de meses desde el último cigarrillo: _____
□ Más de 1 año. → Número de años desde el último cigarrillo: _____

INSTRUCCIONES

En la siguiente página, se le preguntará sobre la primera vez que se enteró de que tenía cáncer. Si ha recibido más de un diagnóstico de cáncer, conteste las preguntas en relación a **su diagnóstico de cáncer más reciente.**

Continúe a la siguiente página.

Sección 2. Consumo de cigarrillos en relación al diagnóstico y el tratamiento del cáncer

7. Para cada uno de los siguientes períodos, indique si fumó cigarrillos todos los días, algunos días o si no fumó.

	Fumó todos los días	Fumó algunos días	No fumó	No sabe/ No está seguro	No corresponde
a. Durante el año antes de que se enterara de que tenía cáncer					□ (No he recibido diagnóstico.)
b. Después del diagnóstico y antes de iniciar el tratamiento					□ (No he recibido diagnóstico.)
c. De 2 días antes de su última cirugía para el cáncer a 2 días después de esta.					□ (No me he sometido a cirugía.)
d. Durante el transcurso del tratamiento					□ (No he recibido tratamiento.)
e. Después de terminar el tratamiento					(No he terminado el tratamiento.)
f. Desde su última consulta en esta clínica					□ (Esta es mi primera consulta en esta clínica.)

8.	Desde la primera vez que se enteró de que tenía cáncer, ¿cuál de los siguientes productos ha consumido con frecuencia?		
	Marque todos los productos que correspondan.		
	 □ Cigarrillos □ Cigarros tradicionales, puros delgados o cigarros con filtro □ Pipas □ Narguile (hookah) □ Cigarrillos de clavo de olor o kreteks □ Bidis □ Tabaco sin humo, húmedo, masticable o rapé □ Snus □ Paan con tabaco, gutka, zarda o khaini □ Ninguno □ Otro, especifique: 		
9.	Desde la primera vez que se enteró de que tenía cáncer, ¿cuál ha sido el período más largo en el que no ha fumado o no fumó?		
	☐ No he fumado desde que recibí el diagnóstico		
	0		
	 □ No fumé por menos de un día □ De 1 a 7 días. → Número de días en que no fumó cigarrillos: □ Menos de 1 mes. → Número de semanas en que no fumó cigarrillos: □ Menos de 1 año. → Número de meses en que no fumó cigarrillos: □ Más de 1 año. → Número de años en que no fumó cigarrillos: □ No sabe / No recuerda 		
Secc	ión 3. Dejar de fumar, productos para dejar de fumar y métodos de ayuda		
10a.	En los últimos 30 días, ¿ha fumado cigarrillos (incluso uno o dos pitadas)?		
	□ Sí □ No → Continúe a la pregunta 11.		

10b.	o. En los últimos 30 días, ¿cuántos días fumó cigarrillos?		
	Número de días Si no fumó, escriba "0".		
11.	Desde que se enteró de que tenía cáncer, ¿cuál de los siguientes productos ha usado para <u>dejar de fumar o evitar fumar</u> cigarrillos?		
	Marque todos los productos que correspondan.		
	 □ Parches de nicotina □ Goma de mascar de nicotina □ Tabletas de nicotina □ Inhalador de nicotina □ Aerosol nasal de nicotina □ Bupropión (Wellbutrin, Zyban) □ Vareniclina (Chantix) □ Cigarrillos electrónicos u otros dispositivos electrónicos de nicotina □ Ninguno □ Otro, especifique:		
12.	Desde que se enteró de que tenía cáncer, ¿qué ayuda ha usado para <u>dejar de fumar o</u> <u>evitar fumar</u> cigarrillos?		
	Seleccione todas las respuestas que correspondan.		
	 □ Orientación individual o grupal □ Línea telefónica de ayuda para dejar de fumar □ Libros o folletos □ Videos □ Sesiones clínicas, clases o grupos de apoyo para dejar de fumar □ Programa de Internet □ Programa para dejar de fumar mediante mensajes de texto □ Apoyo de familiares y amigos □ Ninguna 		
	□ Otra, especifique:		
13.	¿Los médicos que lo tratan para el cáncer le han aconsejado que deje de fumar cigarrillos?		
	 □ Sí □ No □ No corresponde; no he fumado cigarrillos desde que recibí el diagnóstico. 		

14.	En los últimos 30 días, ¿ha estado tratando de dejar de fumar o de evitar fumar cigarrillos?			
	 □ Sí □ No → Continúe a la sección 4. 			
15.	En los últimos 30 días, ¿qué productos, si es el caso, ha usado para dejar de fumar o evitar fumar cigarrillos?			
	Marque todos los productos que correspondan.			
	 □ Parches de nicotina □ Goma de mascar de nicotina □ Tabletas de nicotina □ Inhalador de nicotina □ Aerosol nasal de nicotina □ Bupropión (Wellbutrin, Zyban) □ Vareniclina (Chantix) □ Cigarrillos electrónicos u otros dispositivos electrónicos de nicotina □ Ninguno □ Otro, especifique:			
16.	En los últimos 30 días, ¿qué ayuda ha usado para dejar de fumar o evitar fumar cigarrillos?			
	Marque todas las respuestas que correspondan.			
	 □ Orientación individual o grupal □ Línea telefónica de ayuda para dejar de fumar □ Libros □ Folletos □ Videos □ Sesiones clínicas, clases o grupos de apoyo para dejar de fumar □ Programa de Internet □ Programa para dejar de fumar mediante mensajes de texto □ Apoyo de familiares y amigos □ Ninguna 			

Continúe en la página siguiente.

Sección 4. Uso de otros productos

¿Alguna vez ha usado alguno de los siguientes productos regularmente? 17. Marque todos los productos que correspondan. □ Cigarrillos ☐ Cigarrillos electrónicos u otros dispositivos electrónicos de nicotina ☐ Cigarros tradicionales, puros delgados o cigarros con filtro ☐ Pipas □ Narguile (hookah) ☐ Cigarrillos de clavo de olor o *kretek*s □ Bidis ☐ Tabaco sin humo, húmedo, masticable o rapé □ Snus ☐ Paan con tabaco, gutka, zarda o khaini □ Ninguno □ Otro, especifique: _____ En los últimos 30 días, ¿cuáles de los siguientes productos ha usado? 18. Seleccione todos los productos que correspondan. ☐ Cigarrillos ☐ Cigarrillos electrónicos u otros dispositivos electrónicos de nicotina ☐ Cigarros tradicionales, puros delgados o cigarros con filtro ☐ Pipas □ Narguile (hookah) ☐ Cigarrillos de clavo de olor o *kreteks* □ Bidis ☐ Tabaco sin humo, húmedo, masticable o rapé □ Snus ☐ Paan con tabaco, gutka, zarda o khaini □ Ninguno ☐ Otro, especifique: _____ Sección 5. Exposición al humo en el ambiente 19. ¿Vive actualmente con un fumador? □ Sí □ No

20. En los últimos 30 días...

	Sí	No
a. ¿Ha vivido en algún lugar en donde las personas fumen cigarrillos en el interior?		
b. ¿Ha trabajado en algún lugar en donde las personas fumen cigarrillos en el interior?		

21.	en donde las personas fumen cigarrillos en el interior?					
	☐ Sí ➡ En total, ¿aproximadamente por cuántos años? _☐ No	Si es menos de 1, escriba "1				

22. Teniendo en cuenta todos los años en los que ha trabajado, ¿alguna vez ha trabajado en un lugar en donde las personas fumen cigarrillos en el interior?

□ Sí ➡	En total, ¿aproximadamente por cuántos años?	Si es menos de 1, escriba "1".
□ No		

Gracias por completar este cuestionario.